Table 2.
The characteristics of the included studies.
| Author | Year | Country | Study design | Disease | Number | Cut-off | Median age (years) | Endpoints | NOS |
|---|---|---|---|---|---|---|---|---|---|
|
Kamiya
et al. (14) |
2020 | Japan | Retrospective Single-center |
MM | 178 | ≥5 | CONUT≥5 76 (38-92) CONUT ≤ 4 69 (39-86) | OS, HR=2.364 (1.324-4.220), P=0.004** | 8 |
|
Nagata
et al. (15) |
2020 | Japan | Retrospective Single-center |
DLBCL | 476 | ≥4 | 68.5 (27-97) | OS, HR=1.86 (1.24-2.80), P<0.01** PFS, HR=1.42 (0.98-2.06), P=0.06** | 6 |
|
Matsukawa
et al. (16) |
2020 | Japan | Retrospective multicenter | DLBCL | 615 | >4 | 69 (20-97) | OS, HR=1.53 (1.05-2.23), P=0.028** | 7 |
|
Li
et al. (17) |
2021 | China | Retrospective Single-center |
MM | 119 | >3.5 | 56 (23-83) | OS, HR=1.198 (1.036-1.385), P=0.015** | 7 |
|
ÇAĞLIYAN
et al. (18) |
2021 | Turkey | Retrospective Single-center |
DLBCL | 266 | ≥2 | 64 (23-91) | OS, HR=1.15 (1.04-1.26), P=0.003** PFS, HR=1.19 (1.08-1.31), P=0.001** | 6 |
|
Liang
et al. (10) |
2021 | China | Retrospective Single-center |
MM | 157 | >3.5 | 64 (30-91) | OS, HR=1.191 (0.666-2.129), P=0.556** | 8 |
**multivariate analysis; MM, multiple myeloma; DLBCL, diffuse large B cell lymphoma; NOS, the Newcastle–Ottawa quality assessment Scale.